

# Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2020

<https://marketpublishers.com/r/C84B85C97917EN.html>

Date: February 2020

Pages: 65

Price: US\$ 3,500.00 (Single User License)

ID: C84B85C97917EN

## Abstracts

Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2020

### SUMMARY

According to the recently published report 'Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2020'; Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 6 molecules.

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor. The association of CALCRL with different RAMP proteins produces different receptors which with RAMP1 acts as a receptor for calcitonin-gene-related peptide, with RAMP2 acts as a receptor for adrenomedullin-1 and with RAMP3 act as a receptor for adrenomedullin-2. It plays an important role in treatment of migraine.

The report 'Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2020' outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics

development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 3, 1 and 1 respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Migraine, Trigeminal Neuralgia (Tic Douloureux), Resistant Hypertension and Tension -Type Headache.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)

The report reviews Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics and enlists all their major and minor projects

The report assesses Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Calcitonin Gene Related

Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)  
targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Overview

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Companies Involved in Therapeutics Development

Adephthera LLC

Allergan Plc

Amgen Inc

Biohaven Pharmaceutical Holding Company Ltd

Sosei Heptares

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Drug Profiles

atogepant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BHV-3500 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erenumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-0022562 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rimegepant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target CALCRL and RAMP for Resistant Hypertension - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Dormant Products

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Discontinued Products

Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Product Development Milestones

Featured News & Press Releases

Feb 04, 2020: Appeal panel rules that NICE needs to request evidence for erenumab effectiveness in subgroup of people with chronic migraine

Dec 18, 2019: Biohaven reports positive data from migraine trial of vazegepant

Oct 31, 2019: Cycle Pharmaceuticals and Catalent partner to develop treatments for rare diseases using Zydis ODT Technology

Sep 27, 2019: NICE rejects Novartis' migraine drug Aimovig over data concerns

Sep 12, 2019: Biohaven closes enrolment in vazegepant's Phase II/III study

Sep 09, 2019: Biohaven presents data demonstrating reduction in Migraine-related disability and improvement in patient reported outcomes after oral treatment with Rimegepant at The International Headache Conference Late Breaking Session

Aug 08, 2019: Biohaven completes patient enrolment in rimegepant trial for migraine

Jul 15, 2019: Biohaven's positive phase 3 trial of Rimegepant Zydis orally dissolving tablet for acute treatment of migraine published in The Lancet

Jul 11, 2019: Rimegepant shows positive result as migraine drug in Phase III trial

Jul 11, 2019: Biohaven showcases positive data on Rimegepant, oral CGRP receptor antagonist, with 16 presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting demonstrating efficacy in multiple patient types and long-term safety

Jul 10, 2019: New antibody treatment provides little relief for high-frequency migraine patients

Jul 09, 2019: Allergan provides update on atogepant at the 2019 American Headache

Society Annual Meeting

Jul 03, 2019: Biohaven starts enrolment in rimegepant's trigeminal neuralgia trial

Jul 02, 2019: Novartis' Aimovig yields positive data in open label period

Jul 01, 2019: Novartis data show Aimovig cuts acute migraine medication days by half in patients who failed prior preventive therapies

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Adepthera LLC, H1 2020

Pipeline by Allergan Plc, H1 2020

Pipeline by Amgen Inc, H1 2020

Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2020

Pipeline by Sosei Heptares, H1 2020

Dormant Projects, H1 2020

Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Adephera LLC

Allergan Plc

Amgen Inc

Biohaven Pharmaceutical Holding Company Ltd

Sosei Heptares



## I would like to order

Product name: Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/C84B85C97917EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C84B85C97917EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970